Clinical trials recruiting for Esophageal Adenocarcinoma
15
Recruiting trials
29
US states with sites
16
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 2 |
| AZD5863 | 1 |
| Cabozantinib | 1 |
| Capecitabine | 1 |
| Carboplatin | 1 |
| Cisplatin | 1 |
| DISP-10 | 1 |
| Docetaxel | 1 |
| Durvalumab | 1 |
| KK2269 | 1 |
| M28z1XXPD1DNR CAR | 1 |
| Metformin | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 7 |
| Massachusetts | 6 |
| New York | 6 |
| Texas | 6 |
| Tennessee | 5 |
| Florida | 4 |
| Pennsylvania | 4 |
| Connecticut | 3 |
| Indiana | 3 |
| Ohio | 3 |
| Virginia | 3 |
| Washington | 3 |
Top cities
Boston, Massachusetts 6New York, New York 6Nashville, Tennessee 5Duarte, California 4Fairfax, Virginia 3Houston, Texas 3Los Angeles, California 3New Haven, Connecticut 3Orange, California 3Pittsburgh, Pennsylvania 3
Self-screener
Recruiting trials
- A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- A Study of KK2269 in Adult Participants With Solid Tumors
- A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Determining Minimal Residual Disease Using ctDNA Deep Sequencing
- First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Related conditions
Trials recruiting for Esophageal Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Lung cancer 2180Gastric Adenocarcinoma 13Colorectal cancer 1359Gastroesophageal Junction Adenocarcinoma 11Gastric cancer 91Breast cancer 2239Melanoma 487Hepatocellular carcinoma 51Esophageal Squamous Cell Carcinoma 14
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Esophageal Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.